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2214-0247/Copyright ª 2015, TaiwanAbstract Presently, no satisfactory effective treatment is available to cure diabetes mellitus.
Although synthetic drugs are used, there are several drawbacks. The attributed antihyperglyce-
mic effects of many traditional plants are due to their ability for the management of diabetes
mellitus. This study aimed to investigate the antidiabetic effect of the ethyl acetate fraction
of the seed of Eugenia jambolana in streptozotocin-induced diabetic male albino rats. Diabetic
rats were treated with this fraction at a dose of 200 mg/kg/d for 35 days. Potential antidiabetic
mechanisms were investigated with blood glucose (short-term and long-term model), serum in-
sulin, glycated hemoglobin, study of in situ end-labeling in pancreatic tissue, quantitative
reverse transcription polymerase chain reaction, followed by western blotting study to assess
the hepatic hexokinase-I gene expression, and in-vitro assessment of intestinal maltase and su-
crase activity. Results showed a significant antihyperglycemic action in both short-term and
long-term treatment schedules. Serum insulin and glycated hemoglobin levels were also recov-
ered in the treated group in comparison with the untreated diabetic group (p < 0.05). In situ
end-labeling study focused on the regeneration of pancreatic beta cells in the treated group.
We also observed the correction of expression of the hepatic hexokinase-I gene after the treat-
ment of the fraction in diabetic rats. Intestinal maltase and sucrase activities also displayed in-
hibition activity in the presence of ethyl acetate fraction. The antidiabetic activity of the
fraction was compared with glibenclamide, a standard antidiabetic drug. The findings provide
information about the antihyperglycemic activity of this fraction through gene regulation.
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Diabetes is the world’s fastest increasing metabolic dis-
ease.1 Chronic hyperglycemia is a well-known symptom of
noninsulin dependent diabetes mellitus, which can lead to
the development of diabetic complications.2 There are
several reasons for the enhancement of blood glucose
levels in diabetic patients. A decline in insulin secretion,
defect in the glucose transport system (GLUT4),3 and
enhancement of hydrolytic activity of the intestinal brush
border membrane are three important causes of hypergly-
cemia in diabetic patients.4 Several synthetic drugs are
used for the treatment of diabetes, but no drug is without
side effects and, hence, there is need for alternatives and
improvements to oral hypoglycemic agents.5,6 Anti-
hyperglycemic effects of various plants are credited for
their ability to restore the function of pancreatic tissues by
causing an increase in insulin output or inhibit the intestinal
absorption of glucose or to the facilitation of metabolites in
the insulin dependent processes.7,8 About 400 plant species
with antihyperglycemic properties have been described in
the literature.9 The plant parts contain alkaloids, glyco-
sides, terpenoids, flavonoids, etc., that are frequently used
as antidiabetic agents.10
E. jambolana has been widely used in Indian traditional
medicine for the remedy of various ailments. Different parts
of E. jambolana such as the kernel, leaves, and septum have
a significant antihyperglycemic effect. Antihyperglycemic
potentiality of ethyl acetate fraction of the seed of E.
jambolana has been reported previously by us,11e13 but its
molecular mechanism has not yet been described clearly.
Data on the antidiabetic activity study of this plant part on
molecular level are scanty. Hence, the present study was
conducted to explore the molecular mechanism of action of
ethyl acetate fraction of the seeds of E. jambolana on
streptozotocin (STZ)-induced diabetic rats.Methods
Plant material and extraction
The seeds of E. jambolana were collected from a local
market in Midnapur town and it was authenticated by tax-
onomists in the department of Botany and Forestry,
Vidyasagar University, Midnapore, where voucher speci-
mens were preserved (Bio-Med/V.U/H.A/16/08).The seed
lyophilized crude extract (600 g) was dissolved in 2 L of
hydromethanolic solution (H2O:MeOH, 40:60) followed by
its fractionation using ethyl acetate, as per our previously
reported method.12
Selection of animal and animal care
Wistar strain male albino rats, 3 months of age, weighing
about 120  10 g of matured normoglycemic, with fasting
blood glucose (FBG) levels of 80e90 mg/dL, were used for
this experiment. Rats were housed at an ambient temper-
ature of 25  2C with 12 hour light/12 hour dark cycle.
Rats were provided with protein rich standard feed and
water ad libitum. The principle of laboratory animal careand instructions given by our Institutional Ethical Commit-
tee which is in compliance with the guidelines of Commit-
tee for the Purpose of Control and Supervision of
Experimental Animals, were followed throughout the
experiment.
Induction of diabetes mellitus
Diabetes was induced with a STZ (Sigma Aldrich, St. Louis,
USA) injection at the dose of 40 mg/kg of body weight,
which was dissolved in 0.1M citrate buffer (pH 4.5). Dia-
betes was confirmed 7 days after STZ injection by deter-
mining the FBG concentration. Only animals with FBG levels
300e350 mg/dL were considered for the experiment.14,15
Study Design
Before the induction of diabetes, the rats were divided into
four groups of six animals each.
Control group: Rats of this group were injected of cit-
rate buffer (1 mL/kg body weight) and this group was
subjected to oral administration of 1 mL distilled water/kg
body weight/d for 35 days.
Diabetic group: Rats of this group were made diabetic
with a single intramuscular injection of STZ at a dose of
40 mg/kg body weight. Oral administration of distilled
water was performed for 35 days to diabetic rat at a dose of
1 mL/kg/d body weight.
Ethyl acetate fraction treated diabetic group: Diabetic
rats of this group were treated with ethyl acetate fraction
of seed of E. jambolana at the dose of 200 mg/2 mL
distilled water/kg of body weight/d for 35 days at fasting
state.
Glibenclamide treated diabetic group: Diabetic rats of
this group were treated with glibenclamide at the dose of
20 mg/kg body weight/d for 35 days.
Single dose of ethyl acetate fraction was administered
every day orally at morning (10.00 AM) using intragastric
tube for 35 days. Postprandinal plasma blood glucose levels
were estimated in short-time and long-time models. On 36th
day of extract treatment (42nd day of STZ-injection) all
animals were sacrificed using cervical decapitation. Blood
was collected and serum was separated at 3000 rpm for 10
minutes for the measurement of serum insulin levels. For
mRNA expressions of hepatic hexokinase-I (Hex-I ), the
pancreas and liver were dissected out from each group. To
perform the in situ end-labeling (ISEL) study, the pancreas
was perfused in bouin’s fixative. In a separate experiment,
the inhibitory effects of plant extracts on intestinal sucrase
and maltase were measured with an in-vitro method.
Screening of antihyperglycemic activity
Short-duration experimental model
Blood samples were obtained from the tail vein and FBG
levels were estimated using a glucometer (Bayer’s Ascensia
Entrust, Bayer, Leverkusen, Germany), after 1 hour, 3
hours, 5 hours, 8 hours, and 24 hours following oral
administration of a single dose of ethyl acetate fraction or
glibenclamide samples to rats.
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During the long-term treatment period with ethyl acetate
fraction or glibenclamide, the levels of FBG in all experi-
mental rats were measured using a glucometer (Bayer’s
Ascensia Entrust) at the end of 1 week, 2 weeks, 3 weeks, 4
weeks, and 5 weeks of treatment using blood samples ob-
tained from tail vein.
Assessment of glycated hemoglobin level
Glycated hemoglobin level was measured using glucose
memory test as per standard protocol.16
Quantification of serum insulin level
Serum insulin level was measured using enzyme-linked
immunosorbent assay kit for rats (Boehringer Mannheim
Diagnostic, Mannheim, Germany). Levels of insulin were
expressed in mIU/mL.
ISEL study
ISEL histochemistry was performed using TACS TdT-DAB In
Situ Apoptosis Detection Kit (Trevigen Inc., Gaithersburg,
MD, USA).17
RNA extraction and cDNA synthesis
Hepatic tissue was dissected out from different groups of
experimental rats and immediately allowed to freeze in
liquid nitrogen. The frozen tissue was then pulverized,
resuspended in lysis buffer (Roche Diagnostics, Mannheim,
Germany), and RNA extracted according to the manufac-
turers protocol. Residual DNA was removed with treatment
with 5 units of DNase I (Roche Diagnostics, Mannheim,
Germany) at 37C for 45 minutes followed by inactivation at
65C for 10 minutes. Two micrograms of RNA was reversed
transcribed with superscript II reverse transcriptase. The
cDNA was diluted five-fold prior to polymerase chain reac-
tion (PCR) amplification.
Real-time quantitative PCR
Real-time PCR was performed in the Light Cycler 480
(Roche Diagnostics, Mannheim, Germany) using the SYBR
Green I Master mix (Roche Diagnostics). PCR mixture (final
volume 20 mL) contained 10 mL SYBR Green I mix, 5 mL of
cDNA (1:5 dilution), and 0.5mM of each primer (Hex-I).
Specific Hex-I sequence primers (rat specific) were selected
using the 50 and 30 ends of Hex-I gene sequence as a tem-
plate for PCR amplification, based on the reported rat cDNA
sequence. Specific primer sequences used for PCR were as
follows: Hex-I, sense primer 50-GACCAAGTCAAAAAGATTGA-
30; antisense primer 50-TCTTCTCGTGGTTCACCTGC-30,
yielding an amplified fragment of 256 base pairs.18 Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) primers
were used as an internal control. The PCR cycling profile for
Hex-1mRNA amplification had the following steps. Step 1: T
94C for 10 minutes; step 2: T 94C for 1 minute; step 3: T
62.5C for 1 minute; step 4: T 72C for 1 minute; step 5: go
to step 2 for 30 cycles; and step 6: T 72C for 10 minutes.
Under these conditions, the PCR technique yielded an
exponential amplification of the gene sequence.Semi quantitative western blot analysis
Frozen hepatic tissue was ground in ice-cold radio-
immunoprecipitation buffer (1 mL/g of tissue), and 100 mL
of protease inhibitor cocktail (Roche Applied Science,
Mannheim, Germany) was added. This was frozen at 20C,
thawed, and centrifuged at 15,000 g for 20 minutes at 4C.
The supernatant was then collected. Protein content was
determined using Bradford reagent (Sigma-Aldrich, St
Louis, MO, USA) following the Bradford method.19 Protein
samples (100 mg/well) along with prestained protein
markers (5 mL) were electrophoresed on 14% resolving gel
for 2 hours at 80 V. One gel was transferred to Coomassie
Brilliant Blue stain to check the protein profile, and the
second gel, electrophoresed under identical conditions,
was used for western blot analysis. Resolved protein from
the gel was transferred to the polyvinylidene fluoride
membrane (0.45 mm; Millipore Corporation, Billerica, MA,
USA) using a semidry electroblotting system (Hoefer, Inc.
Holliston, MA, USA) at 150 mA for 1.5 hours. The blot was
rinsed once in Tris buffer saline (TBS; pH 7.5), and blocking
was carried out with 5% nonfat dry milk in TBS with Tween
20 (TBST; pH 7.5) overnight.
Washed blot was incubated with primary mouse mono-
clonal antibody (sc 28885; Santa Cruz Biotechnology Inc.,
Heidelberg, Germany) for Hex-I (110 kDa; 1:200 dilution in
TBST) overnight at 4C. Incubation with rabbit polyclonal
antibody anti-GAPDH (37 kDa; 1:6000 dilution in TBST;
Sigma-Aldrich, St. Louis, MO, USA) served as an internal
control to monitor equal loading of protein. Incubated blot
was washed twice with TBST 1% and once with TBST 0.5%
for 5 minutes each. Blots were incubated with horseradish
peroxidase linked goat antimouse, antirabbit secondary
antibody diluted (1:2000) in TBST (0.5%) at room temper-
ature for 2 hours followed by washing with TBST and TBS,
and the labeled protein bands were visualized using the
DAB system (Bangalore Genei, Bangalore, India). Densito-
metric analysis was performed with LabWorks image anal-
ysis software (Ver 4.0, UVP Inc., Upland, CA, USA).20Inhibition assay for rat intestinal sucrase activity
Sucrase activity was assayed using a standard method with
a slight modification.21,22 Exactly 0.2 mL of 56mM sucrose in
0.1M potassium phosphate buffer (pH 7, 0.2 mL) was mixed
with 0.1 mL of the plant extracts in 50% aqueous dimethyl
sulfoxide. After preincubation at 37C for 5 minutes, 0.2 mL
of rat intestinal sucrase solution prepared from the intes-
tine (cut the small intestine then scrapping the inner part
of the small intestine and mix in 0.9% normal saline) of one
normal rat was added.23 Instead of the plant extract,
0.1 mL dimethyl sulfoxide was used for the blank sample.
After thoroughly mixing, both samples and blank test tubes
were incubated at 37C for 15 minutes and then the reac-
tion was stopped by emerging test tubes in boiling water for
4 minutes. The reaction mixture was passed through a basic
alumina column (6 mm  35 mm) to eliminate phenolic or
acidic compounds. The amount of liberated glucose was
determined with the glucose oxidase assay using a com-
mercial test kit. The optical density (OD) of the wells was
measured at 505 nm and the inhibitory activity was
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(%) Z 100  (1[OD of test sample/OD of control]).
Inhibition assay for rat intestinal maltase activity
Rat intestinal maltase inhibitory activity was determined
using a standard method with a slight modification.21,22 The
assay was carried out in the same manner as the assay of rat
intestinal sucrase inhibitory activity, except for using
3.5mM maltose in 0.1M potassium phosphate buffer (pH 7,
0.35 mL) as a substrate.
Statistical analysis
All data were presented as mean  standard error of the
mean, for six rats in each group. Comparison between
groups or between time points was made with one-way
analysis of variance followed by multiple comparison two-
tail ‘t’ test to analyze the significance study. Differences
were considered significant when p-values were less than
0.05 (p < 0.05). All statistical analysis was performed using
SPSS (SPSS Inc, Chicago, USA).
Results
Effects of ethyl acetate fraction on FBG in short-
term treatment
Table 1, shows the antihyperglycemic activity of ethyl ac-
etate fraction of the seeds of E. jambolana at different
time intervals after a single dose of oral administration of
plant fraction or standard drug, glibenclamide. FBG levels
were decreased gradually from 3 hours to 8 hours after
administration with ethyl acetate fraction or glibencla-
mide; but thereafter, a gradual rise occurred in FBG until 24
hours. The highest reduction of FBG levels was noted in
treated groups at 8 hours. The percentage of recovery in
the fraction treated group was 31%, whereas the gliben-
clamide treated group showed 35% recovery in FBG levels at
8 hours when compared with the initial time (p < 0.05) of
treatment. When comparison was made with the diabetic
group, the percentage of recovery of blood glucose level at
8 hours was 37% in the fraction treated group and 38% in the
glibenclamide treated group.Table 1 Acute effects of ethyl acetate fraction on fasting bloo
Groups
Time (h) af
0 1
Control 69.2  2.3 72  3.5
Diabetic 334.8  6.3 335  8.6
Diabetic þ fraction treated 305.4  13.8 286.8  8.5
Diabetic þ glibenclamide treated 318.7  10.2 279.2  7
*Differ from each other significantly, p < 0.05.
FBG Z fasting blood glucose.
a Data expressed as mean standard error of the mean (nZ 6), analEffect of ethyl acetate fraction on FBG in long-term
treatment
A significant elevation was noted in FBG levels in STZ-
induced diabetic rats in comparison to the control group.
Significant recoveries of FBG levels were noted in the
treated groups in respect to the untreated diabetic group
(Table 2). After daily administration of ethyl acetate frac-
tion or standard drug glibenclamide, at the end of 2 weeks,
3 weeks, 4 weeks, and 5 weeks, the percentage of recovery
of FBG levels were noted at 27%, 57%, 70%, and 73%
respectively, when compared with the untreated diabetic
group (p < 0.05). However, in case of the glibenclamide
treated group, the percentage of recovery was noted at
26%, 59%, 72%, and 74% in respect to the untreated diabetic
group (p < 0.05).
Levels of glycated hemoglobin
Glycated hemoglobin level was increased significantly in
the diabetic group in comparison to the control group. After
treatment with ethyl acetate fraction of the seed of E.
jambolana or glibenclamide, the level of glycated hemo-
globin was resettled towards the control group. Glycated
hemoglobin level was insignificantly different between the
fraction treated and the glibenclamide treated groups
(Figure 1).
Effect of serum insulin
Serum insulin levels were initially decreased in the diabetic
group in respect to the control group. After administration
of ethyl acetate fraction to the diabetic rats for 35 days,
the serum level of this hormone was significantly restored
to the control levels. No significant difference of this
parameter was observed between the fraction-
administered and control groups at 42 days (Figure 1).
Effect of ethyl acetate fraction of seed of E.
jambolana on rat intestinal sucrase and maltase
activities
The inhibitory activity of sucrase by ethyl acetate fraction of
seed of E. jambolana was 26.6% (4.7) and in case of gli-
benclamide (20 mg/kg) treated group the inhibitory activityd glucose levels in streptozotocin-induced diabetic rats.
FBG level (mg/dL)
ter a single dose of fraction administrationa
3 5 8 24
74.4  3.3 71.2  6.4 64.8  2.8 75.2  4.5
345.2  7.1 340.2  3.9 333.8  6.9 346  9.9*
267  6.9 242.4  9.1 211.6  7.76 248.6  9.3*
258.1  8.3 226.5  7.8 208.4  7 252.8  7.8*
ysis of variance followed by multiple comparisons two tail ‘t’ test.
Table 2 Chronic effects of ethyl acetate fraction on fasting blood glucose levels in control and different experimental groups.
Groups FBG level (mg/dL)a
1st d 8th d 15th d 22nd d 29th d 35th d
Control 84.83  4.8 86.83  3.3 81.83  4.7 80.5  4.1 86.32  4.7 88.32  4.1
Diabetic 88.66  4.7 347.6  8.2 353.33  4.1 345.83  4.2 341.33  4.6 346.87  8.2*
Diabetic þ fraction treated 84.16  6.5 345.33  6.4 246  4.6 142.81  4.9 118.11  3.6 102  3.8*
Diabetic þ glibenclamide treated 86.66  4.6 340.66  5.0 241.5  3.6 132.33  3.2 98.8  4.1 89.97  4.9*
* Differ from each other significantly, p < 0.05.
a Data expressed as mean  standard error of the mean (nZ 6), analysis of variance followed by multiple comparisons two tail ‘t’ test.
Figure 1 Protective efficacy of ethyl acetate fraction or glibenclamide on: (A) serum insulin; and (B) glycosylated hemoglobin
levels in streptozotocin-induced diabetic rats. Each bar represents mean  standard error of the mean, nZ 6. Analysis of variance
followed by “multiple comparisons two tail ‘t’ test”. Values of bar diagram with different letters (a,b,c) differ from each other
significantly at the level of p < 0.05. GHb Z glycosylated hemoglobin.
Figure 2 Inhibitory activities of intestinal sucrase and
maltase after ethyl acetate fraction or glibenclamide treat-
ment in streptozotocin-induced diabetic rats. Each bar repre-
sents mean  standard error of the mean, n Z 6 for each
group. Analysis of variance followed by “multiple comparisons
two tail ‘t’ test”. Values of bar diagram with different letters
(a,b) differ from each other significantly at the level of
p < 0.05.
120 K. Jana et al.of sucrase was 29.7% (3.1). The enzymatic inhibition of
maltase by ethyl acetate fraction of seed of E. jambolana
was 31.8% (4.6) and inhibition of maltase by glibenclamide
(20 mg/kg) treated group was 39.7% (1.3) (the data rep-
resents the average of the 3 experiments; Figure 2).
Effect of pancreas on ISEL study
In the control group, very few apoptotic cells were present.
ISEL-positive or apoptotic cells in pancreatic islets were
noted by brown color in the tissue section (Figure 3). More-
over, qualitative analysis revealed more apoptotic cells in
the diabetic group compared with the control group. After
administration of fraction to the diabetic rats, count of ISEL-
positive cells in pancreas was remarkably decreased.
Effect of ethyl acetate fraction of seed of E.
jambolana hepatic Hex-I gene expression
Quantitative real-time PCR densitometric analysis showed
down-regulated expression pattern of the hepatic Hex-I
Figure 3 Immunohistochemistry of the pancreas; in situ end-labeling (ISEL) study,  400, indicates apoptotic cells. (A) Repre-
sentative sample of pancreatic section showing normal density of islet cells and very few apoptotic cells present in the control
group identified by ISEL study; (B) representative sample of pancreatic section showing increase in the number of apoptotic cells
present in diabetic rat by ISEL study; (C) representative sample of pancreatic section from ethyl acetate fraction treated diabetic
rat showing low number of apoptotic cells, identified by ISEL study in comparison to diabetic group; (D) pancreatic section from
glibenclamide treated diabetic rat with low count in apoptotic cells in respect to diabetic group. Scale bar Z 80 mm.
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expression pattern for the same in the control group. A
significant remedial activity of ethyl acetate fraction or
glibenclamide noticed in the said gene expression of above
carbohydrate metabolic marker in target tissue after
treatment in the diabetic group animals (Figure 4).
Western blot analysis
Western blot densitometric analysis of protein of the car-
bohydrate biomarker Hex-I also indicated decreased level
of hepatic carbohydrate metabolism in the diabetic rats
when compared to control rats. A significant (p < 0.05)
remedial activity of ethyl acetate fraction or glibenclamide
on protein level was noticed in the target tissue after
treatment of the animals in the diabetic group (Figure 5).
Discussion
The preamble of chemical induced type-1 diabetes mellitus
in experimental rats is executed using STZ that selectively
destroys pancreatic beta-cells is very convenient and simple
to use.24 STZ causes a massive degeneration of beta-cells of
the islets of Langerhans and induces hyperglycemia through
several processes such as oxidation of essential-sulfhydryl
groups as a conformational probe for the fatty acid synthe-
tase,25 inhibition in glucokinase, disturbances in intracel-
lular calcium homeostasis, or generation of free radicals.26The antihyperglycemic activity of ethyl acetate fraction of
the seed of E. jambolana has been reported previously by
us,11e13 as well as by others,14 but its molecular mechanism
has not yet been described clearly.
In this study, we found the antihyperglycemic potency of
the ethyl acetate fraction of E. jambolana in both short-
term and long-term models may be due to the high solu-
bility of bioactive phytomolecules, i.e., gallic acid and
polyphenolic compounds present in this solvent fraction,
which has been published in our previous publica-
tion.12,13,27 The administration of this fraction at a dose
level of 200 mg/kg of body weight of rat for single admin-
istration attenuates FBG effectively up to 8 hours. This may
be due to the stimulation of pancreatic beta-cells for a
short duration of insulin release against high blood glucose
level by this fraction, the same as the activity produced by
other synthetic oral drugs, like glibenclamide, which is
responsible for the increase in sensitization and stimulation
of beta-cells against blood glucose.28,29 The duration of the
antihyperglycemic effect was up to 8 hours, which may be
due to the molecular instability or rapid plasma clearance
in the physiological system.
In the long-term model, the ethyl acetate fraction
treatment for 35 days exhibited a significant reduction in
the FBG levels towards control of the demonstrated anti-
hyperglycemic property of this herbal fraction. It was also
supported by the significant recovery in serum insulin
levels. These effects may be due to the increased release
of insulin from remaining beta-cells and/or regeneration of
Figure 4 (A). Representative quantitative reverse transcription polymerase chain reaction analysis of hepatic Hex-I gene
expression in rat of different groups (Lane 1: control rat; Lane 2: untreated diabetic rat; Lane 3: ethyl acetate fraction treated
diabetic rat; Lane 4: Glibenclamide treated diabetic rat); (B). Semiquantitative densitometric analysis after normalizing the result
with housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase. Each bar represents mean  standard error of the mean,
nZ 6. Analysis of variance followed by “multiple comparisons two tail ‘t’ test”. Values of bar diagram with different letters (a,b,c)
differ from each other significantly at the level of p < 0.05. A.D.U. Z arbitrary densitometric units; GADPH Z glyceraldehyde-3-
phosphate dehydrogenase.
122 K. Jana et al.beta-cells,14,30 and restoration of insulin sensitivity.31 This
insulinotropic activity was further supported from the low
level of glycated hemoglobin due to lowering of FBG
level,32 as these are under the action of insulin.33
Herbal medicines may exert their antidiabetic activity
by different modes of action, like acting on insulin
secreting pancreatic beta-cells or modifying glucose utili-
zation either by altering the viscosity of gastrointestinal
contents, delaying gastric emptying, or delaying glucose
absorption from the gut by reducing digestion of poly-
saccharide (starch) after food intake.21 Pancreatic sucrase
is the key enzyme in the digestive system that catalyzes the
hydrolysis of sucrose.34 As the activities of these enzymes in
the small intestine correlate to an increase in postprandial
blood glucose level, the inhibition in this level may be an
another important aspect for treatment of diabetes byFigure 5 (A) Representative western blot analysis of Hex-I pro
diabetic rat; Lane 3: ethyl acetate fraction treated diabetic rat; La
analysis of western blots in different experimental groups. Analy
test”. Bars represent mean  standard error, n Z 6. Bars with diff
other. A.D.U. Z arbitrary densitometric units; GADPH Z glyceraldlowering of postprandial blood glucose levels.35 The ethyl
acetate fraction exhibited a significant inhibitory property
against sucrase and maltase activity through in vitro mode,
which was comparable to ‘acarbose’, a standard alpha-D-
glucosidase inhibitor that reversibly inhibits alpha-
glucosidase present in the brush border of the small intes-
tinal mucosa.36 Interference in absorption of dietary car-
bohydrates through the small intestine facilitates this
fraction to exert antihyperglycemic activity.37
The physiological role of hexokinase, the insulin
dependent key carbohydrate enzyme of glycolysis has been
well studied by others,38,39 as well as by us.15 The expres-
sion pattern of Hex-1 in total hepatic lysate of all the
groups was studied through semiquantitative western
blotting and quantitative real-time PCR techniques, which
revealed the diminished expression of Hex-1 in diabetictein in hepatic tissue. Lane 1: control rat; Lane 2: untreated
ne 4: glibenclamide treated diabetic rat; and (B) densitometric
sis of variance followed by “multiple comparisons two tail ‘t’
erent letters (a, b, c) significantly (p < 0.05) differ from each
ehyde-3-phosphate dehydrogenase.
Eugenia jambolana as an antidiabetic agent 123conditions in respect to the control. After 35 days of
chronic treatment, expression pattern of Hex-1 was signif-
icantly improved in the diabetic rat which indicated the
recovery in homeostasis of a carbohydrate similar with the
previous findings of others,40 as well as by us,13 which
supported the hypothesis that higher levels of Hex-1 ac-
tivity reflect a higher rate of glucose utilization by
cells.38,41
The increased loss of beta-cells from the endocrine
pancreas due to STZ-induced free radicals mediated
apoptosis, as shown by an increase of ISEL positive cells,
produces the hyperglycemic status and puts an increased
demand on each single remaining beta-cell to compensate
the increased insulin requirements.42 This insulinopenic
state enhances excess free radicals generation either by
auto oxidation of glucose or enzymatic and nonenzymatic
glycation of proteins with increased formation of glucose
derived advanced glycosylation end products, enhanced
glucose flux through polyol pathway,43 and reduction of
antioxidant defense. The apoptosis-induced reduction in
the beta-cell volume of the pancreas also provide an
explanation for the decrease of glucose tolerance in hy-
perglycemia and the development diabetes mellitus,
which can be controlled by this fraction treatment
following inhibition in absorption of dietary carbohydrates
through small intestine. But after the treatment of the
ethyl acetate fraction or glibenclamide to the diabetic rat,
degeneration of DNA of pancreatic beta-cells was inhibited
which revealed from decreased ISEL positive cells in
immunohistological study. The positive regulation in
expression pattern of Hex-I gene and inhibition in the
breakdown of DNA towards control established its potency
against diabetes may be due to its phytoingredients,
namely gallic acid compounds present in it, as they have
major antioxidative activity with redox properties, as well
as having adsorption and neutralization capacities to free
radicals.44Conclusion
The present study demonstrated that the ethyl acetate
fraction of the seed of E. jambolana has a strong antidia-
betic activity in experimental model rats. It exhibits its
activity through direct inhibition of intestinal glucose
loading, insulinotropic activity, as well as correction in the
carbohydrate metabolic pathway following inhibition in the
hyperglycemia induced apoptosis process.Conflicts of interest
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